PLoS ONE (Jan 2017)
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
- Jesús Troya,
- Pablo Ryan,
- Esteban Ribera,
- Daniel Podzamczer,
- Victor Hontañón,
- Jose Alberto Terrón,
- Vicente Boix,
- Santiago Moreno,
- Pilar Barrufet,
- Manuel Castaño,
- Ana Carrero,
- María José Galindo,
- Ignacio Suárez-Lozano,
- Hernando Knobel,
- Miguel Raffo,
- Javier Solís,
- María Yllescas,
- Herminia Esteban,
- Juan González-García,
- Juan Berenguer,
- Arkaitz Imaz,
- GESIDA-8314 Study Group
Affiliations
- Jesús Troya
- Pablo Ryan
- Esteban Ribera
- Daniel Podzamczer
- Victor Hontañón
- Jose Alberto Terrón
- Vicente Boix
- Santiago Moreno
- Pilar Barrufet
- Manuel Castaño
- Ana Carrero
- María José Galindo
- Ignacio Suárez-Lozano
- Hernando Knobel
- Miguel Raffo
- Javier Solís
- María Yllescas
- Herminia Esteban
- Juan González-García
- Juan Berenguer
- Arkaitz Imaz
- GESIDA-8314 Study Group
- DOI
- https://doi.org/10.1371/journal.pone.0172184
- Journal volume & issue
-
Vol. 12,
no. 2
p. e0172184
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0164455.].
